A phase II study of intravenous TZT-1027 [soblidotin] administerd weekly times two every three weeks to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to anthracycline-based chemotherapy
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Soblidotin (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Paraganglioma; Rhabdomyosarcoma; Sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 15 May 2012 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 23 Sep 2005 New trial record.